和黄医药涨超5%,因在ASCO年会上公布了SACHI III期临床试验数据,该研究探索赛沃替尼和奥希替尼联合疗法治疗特定非小细胞肺癌患者,并已达到主要终点,新药上市申请已获中国药监局受理。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.